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Mutations affecting glycinergic
neurotransmission in hyperekplexia increase
pain sensitivity
Pascal Henri Vuilleumier,1 Raphael Fritsche,2 Jürg Schliessbach,1 Bernhard Schmitt,3
Lars Arendt-Nielsen,4 Hanns Ulrich Zeilhofer5 and Michele Curatolo4,6
Inhibitory interneurons in the spinal cord use glycine and GABA for fast inhibitory neurotransmission. While there is abundant
research on these inhibitory pain pathways in animal models, their relevance in humans remains unclear, largely due to the limited
possibility to manipulate selectively these pathways in humans. Hyperekplexia is a rare human disease that is caused by loss-of-
function mutations in genes encoding for glycine receptors and glycine transporters. In the present study, we tested whether
hyperekplexia patients display altered pain perception or central pain modulation compared with healthy subjects. Seven patients
with genetically and clinically confirmed hyperekplexia were compared to 14 healthy age- and sex-matched controls. The following
quantitative sensory tests were performed: pressure pain detection threshold (primary outcome), ice water tolerance, single and
repeated electrical pain detection thresholds, nociceptive withdrawal reflex threshold, and conditioned pain modulation. Statistical
analysis was performed using linear mixed models. Hyperekplexia patients displayed lower pain thresholds than healthy controls
for all of the quantitative sensory tests [mean (standard deviation)]: pressure pain detection threshold [273 (170) versus 475 (115)
kPa, P = 0.003], ice water tolerance [49.2 (36.5) versus 85.7 (35.0) s, P = 0.015], electrical single pain detection threshold [5.42
(2.64) versus 7.47 (2.62) mA, P = 0.012], electrical repeated pain detection threshold [3.76 (1.41) versus 5.8 (1.73) mA, P = 0.003],
and nociceptive withdrawal reflex [7.42 (3.63) versus 14.1 (6.9) mA, P = 0.015]. Conditioned pain modulation was significantly
reduced in hyperekplexia [increase to baseline: 53.2 (63.7) versus 105 (57) kPa, P = 0.030]. Our data demonstrate increased pain
sensitivity and impaired central pain modulation in hyperekplexia patients, supporting the importance of glycinergic neurotrans-
mission for central pain modulation in humans.
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Introduction
Synaptic inhibition in nociceptive pathways of the spinal
cord is mediated by glycine and GABA receptors
(Zeilhofer, 2005). Glycine receptors are the major deter-
minants of inhibitory neurotransmission in the retina,
spinal cord and brainstem (Lynch, 2004; Chung et al.,
2010). Immunofluorescence studies have confirmed abun-
dant glycinergic innervation in the dorsal horn (Zeilhofer
et al., 2005), a key site in the classic gate control theory of
pain (Melzack and Wall, 1965). Animal studies have
shown that non-nociceptive reactions are non-nociceptive
only as long as spinal GABAergic and glycinergic inhibition
remain intact (Zeilhofer, 2008; Foster et al., 2015). Glycine
receptors are members of the pentameric ligand-gated ion
channel family, which belongs to the same superfamily of
Cys-loop receptors as the 5HT3, nicotinic acetylcholine and
GABAA/C receptors (Lynch, 2009). Glycine receptors are
membrane-embedded proteins that contain an integral
chloride-selective pore (Lynch, 2004). GABA and glycine
open chloride channels, which hyperpolarize postsynaptic
cells and impair the propagation of excitatory signals on
dendrites of neurons (Zeilhofer, 2005; Lynch, 2009).
Pharmacological blockade of GABAergic and/or glyciner-
gic neurotransmission in the dorsal horn mimics many
symptoms of inflammatory and neuropathic pain (Sivilotti
and Woolf, 1994; Sherman and Loomis, 1995; Zeilhofer
and Zeilhofer, 2008). Additionally, a loss of synaptic in-
hibition in the dorsal horn occurs in animal pain models
(Coull et al., 2003, 2005; Muller et al., 2003; Harvey et al.,
2004b). In humans, studies on nociceptive long-term po-
tentiation suggest that loss of inhibitory interneurons in
the dorsal horn may play a role in the development of
chronic pain (Klein et al., 2004). However, the importance
of central inhibitory mechanisms in human pain states is
difficult to prove, largely due to the limited possibility to
manipulate these pathways in humans.
In humans, impairment of spinal glycine receptors or asso-
ciated proteins is responsible for hyperekplexia, a rare
neurogenetic disease (OMIM #149400). Hyperekplexia,
also known as hereditary startle disease or stiff baby
syndrome, is a non-epileptic disorder characterized by an
exaggerated persistent startle response and neonatal hyper-
tonia to unexpected auditory, somatosensory and visual
stimuli (Andermann et al., 1980; Praveen et al., 2001;
Zhou et al., 2002). Startle responses and generalized
muscle stiffness both gradually subside during the first
months of life (Tijssen and Rees, 2007). However, patho-
logical startle responses can remain throughout adulthood,
resulting in unprotected falls and injury (Andermann et al.,
1980). These features characterize the major form of
hyperekplexia.
To date, hereditary hyperekplexia has been identified in
4100 pedigrees and 4120 sporadic cases (Dreissen and
Tijssen, 2012). Most of them are classified as the major
form of hyperekplexia. There is a minor form of the
disease, described in few families, but this condition may
remain under-reported (Bakker et al., 2006).
To date, mutations in five genes encoding for different
key elements of inhibitory glycinergic synapses have been
associated with hyperekplexia (Shiang et al., 1993; Brune
et al., 1996; Humeny et al., 2002; Rees et al., 2002). Two
of these genes (GLRA1 and GLRB) encode for glycine re-
ceptor subunits. Additionally, defects in the presynaptic gly-
cine transporter gene GLYT2 (SLC6A5) have been
identified in human hyperekplexia (Eulenburg et al.,
2006; Rees et al., 2006). GPHN, encoding the glycine re-
ceptor clustering molecule gephyrin (Rees et al., 2003), and
ARHGEF9, an X-linked gene encoding collybistin (Harvey
et al., 2004a), are each associated with known cases of
hyperekplexia (Tijssen and Rees, 2007).
The aim of this study was to evaluate, for the first time in
humans, whether symptomatic mutations in the glycinergic
system affects central pain processing.
Materials and methods
This study was conducted in accordance with the amended
Declaration of Helsinki. The study was approved by the IRB
of the Canton Bern, Switzerland (No. 131/11). It was regis-
tered in the Clinical Trials Protocol Registration System
(NCT01476514). All subjects gave written informed consent.
Design
This was a prospective study of pain thresholds in hyperek-
plexia patients and a group of sex- and age-matched healthy
volunteers. To avoid experimenter bias, quantitative sensory
tests of hyperekplexia patients and healthy volunteers were
assessed independently by different investigators: R.F. and
J.S. tested healthy volunteers and P.V. tested patients with
hyperekplexia. P.V. previously trained and extensively super-
vised R.F. and J.S. on standardized quantitative sensory test
measurements, with the aim to maximize inter-observer
reliability for investigations that were performed before the
present one (Biurrun Manresa et al., 2014; Vuilleumier
et al., 2015).
Setting
The experiments were performed at the Department of
Anaesthesiology and Pain Medicine, Bern University
Hospital, Bern, University of Bern, Switzerland.
Participants
Seven patients with the major form of hyperekplexia and 14
sex- and age-matched healthy volunteers were studied. They
received a compensation of 150 Swiss francs for their partici-
pation, plus reimbursement for travel expenses. Healthy con-
trols were recruited by advertisement at the Bern University
Hospital; patients with hyperekplexia were recruited by contact-
ing neuropaediatricians and neurologists known to care for
these patients in Switzerland, Germany, France, the UK, Italy
and Washington State, USA. Inclusion criteria for hyperekplexia
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patients were a clinically major form of hyperekplexia diag-
nosed by a neuropaediatrician or neurologist and a known mu-
tation in one of the following: GLRA1, GLRB, SLC6A5
(GlyT2), GPHN, glycine receptor clustering molecule gephyrin
or ARHGEF9. Exclusion criteria were: age below 7 years,
pregnancy or breastfeeding, an ongoing treatment with
antidepressant drugs, opiates or any analgesic substance
during the 10 days before testing, and cognitive deficits, defined
as an adult not able to fulfil basic professional activities or a
child not able to attend regular school classes. Baseline treat-
ment for hyperekplexia (specified in Table 1) was not discon-
tinued for ethical reasons. Healthy controls were selected to
match hyperekplexia patients by gender and age (2 years
and 5 years for patients 518 and 518 years old, respect-
ively). Exclusion criteria for the control group were any chronic
or acute pain, any neuropathy interfering with quantitative
sensory measures, intake of any medication known to modulate
pain perception or quantitative sensory measures, any drug or
substance abuse, pregnancy and breastfeeding.
End-points
The pressure pain detection threshold on the second toe was
the primary end-point. This test was chosen because, in previ-
ous studies, it discriminated children with growing pain from
healthy controls (Hashkes et al., 2004). Additional measures
were used as secondary end-points.
General methodological aspects
Participants were positioned in a comfortable supine position
with the upper body elevated by 30 in a quiet room dedicated
to pain research. Tests were performed on the dominant body
side, except for ice-water stimulation, which was applied to the
non-dominant body side. Whenever children 412 years old
were tested, one or both of the parents were present during
the testing. For subjects between 12 and 17 years of age, par-
ent’s presence was discussed in advance and always allowed
whenever desired or indicated. Training sessions for the pain
tests were performed before beginning data collection; the
training lasted until the subjects were familiar with the testing
procedures. Participants were not informed about the expected
results to avoid conditioning.
Pressure pain detection threshold
The pain detection threshold was measured with an electronic
pressure algometer (Algometer, Somedic) applied at the centre
of the pulp of the second toe. The probe had a surface area of
1 cm2. The pressure was increased from 0 at a rate of 30 kPa/s
to a maximum pressure of 1000 kPa. The pain detection
threshold was defined as the point at which the pressure sen-
sation turned to pain. The subjects were instructed to press a
button when these points were reached. The algometer dis-
played the pressure intensity at which the button was pressed.
If the subjects did not press the button at a pressure of
1000 kPa, this value was considered to be the threshold.
Three assessments were made for the data analysis.
Thresholds to cutaneous electrical stimulation and
nociceptive withdrawal reflex
Cutaneous electrical stimulation was performed through bipo-
lar surface Ag/AgCl-electrodes (Alpine Biomed Adhesive
Disposable Surface Electrodes) placed just distal to the lateral
malleolus (i.e. innervation area of the sural nerve). EMG reflex
responses to electrical stimulation were recorded from the
middle of the biceps femoris and the rectus femoris muscles
(Ag/AgCl-electrodes). Stimulation and EMG recordings were
made by a computer-controlled constant current stimulator
(NCS System, Evidence 3102 evo, Neurosoft).
A 25 ms, train-of-five, 1 ms, square-wave impulse (perceived
as a single stimulus), was delivered to the skin. The current
intensity was increased from 1 mA in steps of 0.5 mA until
(i) a biceps femoris reflex with an amplitude exceeding 20 mV
for at least 10 ms in the 50–150 ms post-stimulation interval
was detected (i.e. single stimulus reflex threshold); and (ii) a
pain sensation was evoked (i.e. single stimulus pain threshold).
For repeated (i.e. five stimuli) cutaneous stimulation, the
stimulus burst used for single stimulation was repeated five
times at 2 Hz, at constant intensity. The current intensity of
the five stimuli was increased from 1 mA in steps of 0.5 mA
until the subjects felt pain during the last two to three of the
five stimuli. Three assessments were made and averaged for
data analysis.
Heat and cold pain detection thresholds
For heat stimulation, a 30  30 mm thermode was applied to
the skin (TSA-2001, Medoc). The test was performed at the
Table 1 Demographics of seven hyperekplexia patients and 14 healthy controls
Hyperekplexia Healthy controls
Mutation Age Gender Medication Weight
(kg)
Height
(cm)
BMI Mean
age
Mean
weight (kg)
Mean
height (cm)
Mean
BMI
SLC6A5 10 M Clonazepam 28 132 16.1 10 36.5 146.5 17.0
GLRA1 34 F Clonazepam 62 164 23.1 34.5 64 169 22.4
GLRA1 14 M Clonazepam 56 157 22.7 14.5 51.5 160 20.1
GLRA1 35 F Desoxyphenobarbital,
gabapentin
72 168 25.5 39 61.7 163.5 23.1
GLRA1 28 M Diazepam 51 163 19.2 27.5 61 167.5 21.7
GLRA1 40 M Clonazepam 73 179 22.8 41 81 176.5 26
GLRA1 12 M Valproate, clobazam 50 155 20.8 13.5 52 160.5 20.2
Two matched controls were used for each patient.
BMI = body mass index; F = female; M = male.
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lateral aspect of the leg, midway between the knee and the
lateral malleolus (Neziri et al., 2011). The temperature of the
thermode was continuously increased from 30C to a max-
imum of 50.5C at a rate of 1.0C/s. The pain detection
threshold was defined as it was for pressure stimulation. The
subjects were instructed to press a button when the thresholds
were reached. At that point, the temperature was recorded and
the thermode cooled to 30C. The thermode also cooled to
30C even if the detection threshold was not reached at
50.5C, in which case 50.5C was considered to be the
threshold.
Cold stimulation was performed with the same apparatus
and thermode as heat stimulation. The temperature of the
thermode was continuously decreased from 30C to a min-
imum of 0C at a rate of 1.0C/s. The cold pain detection
threshold was defined as it was for pressure stimulation. The
subjects were instructed to press a button when the threshold
was reached. At that point, the temperature was recorded by
the software and the thermode heated to 30C. If the threshold
was not reached at 0C, 0C was considered to be the thresh-
old. The test was performed at the same site as heat
stimulation.
Ice water test
The hand was immersed in ice-saturated water (0.7  1C).
The device consisted of a container separated by a mesh
screen into an outer and inner part. The mesh screen prevented
direct contact between the ice (placed in the outer part) and
the hand of the subject (placed in the inner part). The water
was regularly stirred to maintain the temperature in the inner
part at 0.7  1C, as monitored by a digital thermometer
(  0.1C).
The subjects placed their hands, wide open and submerged
up to the wrist, into the container. They were asked to keep
their hands in the water until an intolerable sensation of pain
was perceived or for a maximum of 2 min. The time from
immersion to withdrawal was recorded.
Conditioned pain modulation
Pressure pain applied to the second toe and an ice water test
applied to the hand were used as ‘test’ and ‘conditioning’
stimuli, respectively. Pressure pain detection threshold was
measured at the same time as the subject was withdrawing
the hand from the ice water. An increase in the pressure
pain detection threshold immediately after the ice water test
was considered an indication of functioning conditioned pain
modulation (Serrao et al., 2004; Vuilleumier et al., 2013).
Descriptive variables
Age, gender, weight and body mass index were recorded for
all participants. Any ongoing medical treatment was recorded
for hyperekplexia patients.
Sample size considerations
The sample size was calculated based on previous data on the
pressure pain detection threshold in children with growing pains
and healthy controls (Hashkes et al., 2004). Assuming a mean
value of 579 and 500 kPa in controls and patients, respectively,
expecting a standard deviation of 108 kPa, and setting a ratio of
2:1 between the two groups, 45 controls and 23 patients were
required to detect a difference in the pain detection threshold
between the two groups at a two-sided alpha-level of 5% with a
power of 80%. Due to the rarity of the disease, recruitment was
extremely difficult. The study was closed after failing to recruit
new patients over 2 years.
Statistical analysis
The differences between cases and controls were estimated
using linear mixed models with random intercepts for each
matched case-control group [i.e. yij = b0 + xij b1 + ui + "ij for
case-control pair i and patient j with ui  N(0,
2) and
"ij  N(0,
2) and xij = 0 for controls and xij = 1 for cases].
The models were estimated by restricted maximum likelihood.
The sampling distributions of the test statistics were approxi-
mated by a t-distribution using the method from Kenward and
Roger (1997) with the expected information matrix. One vari-
able was modelled on the log-scale to improve the model fit
(ice water tolerance). The group difference is expressed as
mean difference or geometric mean ratio (for the variables
modelled on log-scale) with a 95% confidence interval (CI)
and a P-value. The analysis was performed in Stata 14
(StataCorp. 2015, Stata Statistical Software: Release 14.
College Station, TX: StataCorp LP).
Results
Of the seven patients enrolled, three were recruited in
Switzerland and four in Germany. Six of our patients car-
ried mutations in the GLRA1 gene, one patient had a mu-
tation in the SCL6A5 gene. All of them were tested in Bern,
Switzerland. All tested hyperekplexia patients were devoid
of acute or chronic pain syndromes, as well as devoid of
obvious sensory impairments. No startle response was
evoked during the quantitative sensory test measures.
Table 1 presents the demographics of the hyperekplexia
patients and the healthy controls. Table 2 presents the base-
line values and the statistical analysis of the performed
quantitative sensory tests. Figure 1 illustrates the results
of pressure pain detection thresholds (i.e. the primary
end-point) and electrical pain detection thresholds as well
as the nociceptive withdrawal reflex threshold, the cold
pressor test and conditioned pain modulation baseline
shifts.
In the analysis of the primary outcome variable, pressure
pain detection thresholds were significantly lower in hyper-
ekplexia patients than in controls (P = 0.003; mean differ-
ence 201 kPa, 95% CI: 82–321).
The cutaneous electrical single-stimulus pain detection
threshold in hyperekplexia patients was significantly lower
(P = 0.012) than in controls, with a mean difference of 2.05
mA (95% CI: 0.54–3.56). Cutaneous electrical repeated-
stimulus (temporal summation) pain detection thresholds
were also significantly lower in hyperekplexia patients
(P = 0.003) than in controls, with a mean difference of
2.05 mA (95% CI: 0.85–3.24). The threshold for the noci-
ceptive withdrawal reflex was also significantly decreased in
hyperekplexia (P = 0.024), with a mean difference from
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controls of 6.67 mA (95% CI: 1.05–12.29). In one hyper-
ekplexia patient, the nociceptive withdrawal reflex could
not be assessed because the increase in current intensity
caused intolerable pain before eliciting a reflex. The
nociceptive withdrawal reflex was not assessed in the
corresponding controls.
Time tolerated in the ice-water was significantly shorter
in hyperekplexia patients (P = 0.015) than in healthy
Table 2 Results from linear mixed models of pain tests
Hyperekplexia (n = 7)
Mean (SD)
Controls (n = 14)
Mean (SD)
Mean difference or
GMR (95% CI)
P-value
PPDT (kPa) 273 (170) 475 (115) 201 (82–321) 0.003
CPM (kPa) 53.2 (63.7) 105 (57) 52.1 (6.0–98.3) 0.030
ESPD (mA) 5.42 (2.64) 7.47 (2.62) 2.05 (0.54–3.56) 0.012
ERPD (mA) 3.76 (1.41) 5.80 (1.73) 2.05 (0.85–3.24) 0.003
NWR (mA)a 7.42 (3.63) 14.1 (6.9) 6.67 (1.05–12.29) 0.024
IWT (s)b 49.2 (36.8) 85.7 (35.0) 1.97 (1.17–3.32) 0.015
aOne and two patients with missing data in the hyperekplexia and control group, respectively.
bTreatment effect expressed as geometric mean ratio (GMR).
CPM = conditioned pain modulation (change from baseline); ERPD = cutaneous electrical repeated-stimulus pain detection threshold; ESPD = cutaneous electrical single-stimulus
pain detection threshold; IWT = ice water tolerance time; NWR = nociceptive withdrawal reflex; PPDT = pressure pain detection threshold.
Figure 1 Pain tests. Bars show the mean values with 95% CI or the geometric mean value with 95% CI for the ice water tolerance time.
*P5 0.05. **P5 0.005.
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controls, with a mean difference of 1.97 s (95% CI: 1.17–
3.32).
The heat pain detection threshold and cold pain detection
threshold could not be fit to the statistical model because of
a severe violation of the model assumption, and they were
not tested for significance. The heat pain detection thresh-
old had a mean value of 45.6C [standard deviation
(SD) = 4.24C] in hyperekplexia patients and 48.5C
(SD = 2.05C) in controls. The cold pain detection thresh-
old had a mean value of 7.72C (SD = 9.57C) in hyper-
ekplexia patients and 1.62C in controls (SD = 4.55C).
Conditioned pain modulation was significantly less effect-
ive in hyperekplexia patients (P = 0.030), as they displayed
a reduced increase in the pressure pain threshold (i.e. test
stimulus) from baseline; the mean difference between the
two groups was 52.1 kPa (95% CI: 6.0–98.3).
A retrospective sensitivity analysis with additional
healthy controls was performed and is presented in the
Supplementary material.
Discussion
This study investigated the influence of documented muta-
tions in glycine signalling on pain modulation in humans.
Remarkably, very large differences between patients and
controls in multiple pain modalities and pain mechanisms
(temporal summation and descending pain modulation)
were found. The results are highly suggestive of altered
central pain processing (gain-of-function) associated with
dysfunction in inhibitory glycinergic synaptic transmission.
Many dorsal horn neurons receive both GABAergic and
glycinergic synaptic input, hence there is significant overlap
in glycinergic and GABAergic neurotransmission in the
spinal cord. Fast postsynaptic inhibitory responses mostly
exhibit two distinct kinetic patterns: a glycinergic strych-
nine-sensitive component with fast decay and a slower
GABAergic bicuculline-sensitive component. Although it is
well established that there is a co-release of GABA and
glycine from the same synaptic vesicles, their respective ef-
fects on postsynaptic inhibition are not entirely understood
(Zeilhofer et al., 2012). Because of the close relationship
between GABAergic and glycinergic neurotransmission, the
following discussion includes data on pharmacological
modulation of both pathways.
Pressure pain
Glycinergic interneurons modulate the processing of mechan-
ical input from low threshold mechanoreceptive afferents to
central pain projection neurons (Powell and Todd, 1992;
Zeilhofer, 2005). Narikawa et al. (2000) detected inhibitory
postsynaptic currents (IPSCs) in laminae II of the spinal horn
after in vivo mechanical stimulation of rodent skin. The gly-
cine antagonist strychnine and the GABAA antagonist bicucul-
line abolished these IPSCs. These data may explain our
findings, with significantly lower pressure pain detection
thresholds in hyperekplexia patients than in healthy controls.
Interestingly, pressure pain detection and tolerance thresholds
were unaffected by the GABAA modulators clonazepam or
clobazam in a study on healthy volunteers (Vuilleumier
et al., 2013), possibly because of low sensitivity of these
pain tests in a human pharmacological model, whereby
safety considerations limit the doses administered.
Electrical pain and nociceptive reflex
thresholds
There is limited literature on glycinergic modulation of pain
with cutaneous electrical stimulation. The benzodiazepines
clobazam and clonazepam, which enhance GABAergic inhib-
ition, have been tested in 16 healthy volunteers in a cross-
over design; while single or repeated cutaneous electrical
stimulation failed to detect significant differences between
the benzodiazepines and the placebo, pain thresholds with
intramuscular electrical stimulation were increased after clo-
bazam and clonazepam administration (Vuilleumier et al.,
2013). Another study with healthy volunteers testing clona-
zepam and clobazam also failed to detect significant differ-
ences from placebo in pain thresholds after cutaneous
electrical stimulation, as well as with the nociceptive with-
drawal reflex (Besson et al., 2015). These results are in con-
trast with the findings of the present study, again suggesting
that the mandatory use of low doses in humans may prevent
tests with limited sensitivity to detect analgesic effects. Our
study suggests that modulation of painful electrical stimuli is
compromised in patients with impaired glycinergic neuro-
transmission. The lower nociceptive withdrawal reflex in
hyperekplexia patients, compared with healthy controls,
strongly suggests that the impairment in glycinergic central
pain modulation occurs, at least in part, at the spinal level.
Thermal pain thresholds
The ice water test revealed significantly lower cold toler-
ance in hyperekplexia patients than in healthy controls. In
a study performed by our group, there was no significant
effect of clobazam and clonazepam on ice water tolerance
in healthy volunteers (Vuilleumier et al., 2013). These
contradictory findings might be explained by a stronger
glycinergic than GABAergic control over ice water toler-
ance thresholds. Delta9THC is not only an agonist at can-
nabinoid receptors but also acts as a positive allosteric
modulator of glycine receptor (Xiong et al., 2014). In a
study of 42 volunteers, smoking cannabis significantly pro-
longed hand immersion times in ice water (Cooper and
Haney, 2016), perhaps partly due to modulation of
glycinergic signalling.
Conditioned pain modulation
Conditioned pain modulation is the human counterpart of
diffuse inhibitory noxious stimulation, whereby a condi-
tioning stimulus is expected to reduce pain caused by a
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test stimulus (Yarnitsky et al., 2010). It has been postulated
that conditioned pain modulation activates descending in-
hibitory fibre tracts from the subnucleus reticularis dorsalis
terminating in the dorsal horn, where serotoninergic and
noradrenergic mechanisms contribute to pain modulation
(Bouhassira et al., 1992; Bannister et al., 2009).
Norepinephrine has been shown to facilitate inhibitory
transmission in the adult rat spinal cord through the acti-
vation of 2 adrenoceptors (Nabekura et al., 1999). Baba
et al. (2000) found that norepinephrine dose-dependently
increases GABAergic and glycinergic IPSCs in the rodent
spinal cord. In an in vivo spinal nerve ligation model, in
which diffuse noxious inhibitory control is abolished,
Bannister et al. (2015) were able to restore diffuse inhibi-
tory noxious stimulation with the norepinephrine reuptake
inhibitor reboxetine.
The present study shows that conditioned pain modula-
tion is significantly impaired in hyperekplexia patients,
whereas a previous study performed by our group
showed that classical allosteric modulators of GABAA re-
ceptors did not produce any effect on conditioned pain
modulation in healthy volunteers (Vuilleumier et al.,
2013), confirming previous results (Kunz et al., 2006).
This may suggest that conditioned pain modulation de-
pends more on glycinergic than on GABAergic neurotrans-
mission in humans.
However, a partial answer may stem from the finding in
rodents that there is a gradient of inhibitory input in the
dorsal horn: glycinergic inhibition is most pronounced in
the deep dorsal horn and the inner lamina II; GABAergic
inhibition is most pronounced in the outer lamina II to
lamina I (Takazawa and MacDermott, 2010). Fibres trans-
mitting low threshold innocuous input terminate in lamina
III and lamina II, where glycine is the predominant fast
neurotransmitter (Takazawa and MacDermott, 2010;
Imlach et al., 2016). This might explain the differential
behaviour of conditioned pain modulation/diffuse inhibi-
tory noxious stimulation with respect to glycinergic and
GABAergic inhibition: the fibres mediating the conditioning
stimulus of conditioned pain modulation/diffuse inhibitory
noxious stimulation predominantly end in the inner lamina
II region, where glycine receptors dominate fast neuronal
inhibition, linking an innocuous sensory input to fast gly-
cinergic hyperpolarization and conditioned pain modula-
tion efficiency. Although co-release of GABA and glycine
has been shown (Todd et al., 1996; Zeilhofer et al., 2012),
the effects of reductions in glycinergic neurotransmission
are indeed delicate in comparison with positive
GABAergic stimulation.
Strength and limitations
To our knowledge, no prior study assessed central pain
modulation in humans diagnosed with hyperekplexia, a
human disease associated with documented glycinergic dys-
function. We have applied a wide spectrum of pain tests.
The ability to study human pain pathophysiology in the
face of documented defects in glycinergic neurotransmission
is an important translational step in clarifying the role of
this pathway in human pain conditions. All patients
included had a confirmed symptomatic mutation in glycine
signalling, and did not suffer from any chronic musculo-
skeletal or neuropathic pain condition that could have per
se determined the findings. The main limitation is the small
sample size, which may have produced false positive re-
sults. However, the measured differences were, quantita-
tively, large in virtually all tests, and the results were
consistent across the different pain modalities, suggesting
that the results reflected true group differences, which
was confirmed by a sensitivity analysis. Medication was
not stopped in hyperekplexia patients for ethical reasons.
As baseline medication used in hyperekplexia patients may
increase pain thresholds, this may have affected the preci-
sion of the estimates and reduced the differences between
the two groups. However, the conclusions of the study
would not be affected. Anxiety and hypervigilance may
be observed in hyperekplexia patients (Kar et al., 2013),
and these factors may contribute to altered quantitative
sensory tests independent of the presence of hyperekplexia.
However, data on the influence of these factors on quanti-
tative sensory tests are not consistent, with several investi-
gations showing no influence on measures of pain
sensitivity and spinal nociceptive excitability (Neziri et al.,
2010; Rhudy et al., 2011; Terry et al., 2012; Biurrun
Manresa et al., 2013; Curatolo et al., 2015). While mini-
mizing observer bias by testing hyperekplexia patients and
healthy controls by different investigators, this might have
introduced inter-observer variability to the quantitative
sensory test measurements. However, several studies have
consistently reported satisfactory to excellent inter-observer
reliability of quantitative sensory test measures, when per-
formed in a standardized setting by trained investigators
(Geber et al., 2011; Nikolajsen et al., 2011; Dyck et al.,
2014; O’Neill and O’Neill, 2015; Boland-Freitas et al.,
2016; Duffy et al., 2017).
Conclusions
Using a model of human genetic disease, this study
provided evidence that glycinergic transmission is import-
ant in human pain processing and that loss-of-function mu-
tations in genes encoding for glycine receptors and glycine
transporters cause gain-of-function in the pain system.
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